$IVA #Inventiva SA INVENTIVA : Lanifibranor - above and beyond what’s expected: Inventiva establishes itself as a force to be reckoned with in the NASH field with the NATIVE trial data of panPPAR agonist lanifibranor. Impact on both NASH… https://t.co/4PVrUfTkO9 #equity #stocks https://t.co/9Sv4yttMpp